Clinical Trials

25 studies in Hematology-Oncology - Arizona

  1. A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
    1. Arizona
  2. A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
    1. Arizona
  3. Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: a Phase I Study
    1. Florida
    2. Minnesota
  4. A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)
    1. Florida
  5. Gene Analysis for the Understanding of Barrett's Esophagus and Esophagus Cancer
    1. Arizona
    2. Florida
    3. Minnesota
  6. A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
    1. Arizona
  7. Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
    1. Arizona
  8. Viral Therapy in Treating Patient With Liver Cancer
    1. Arizona
  9. Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
    1. Arizona
  10. A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
    1. Arizona
    2. Minnesota
  1. 1
  2. 2
  3. 3
  4. Next

Clinical Trials

25 studies in Hematology-Oncology - Arizona

  1. A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
    1. Arizona
  2. A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
    1. Arizona
  3. Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: a Phase I Study
    1. Florida
    2. Minnesota
  4. A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)
    1. Florida
  5. Gene Analysis for the Understanding of Barrett's Esophagus and Esophagus Cancer
    1. Arizona
    2. Florida
    3. Minnesota
  6. A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
    1. Arizona
  7. Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma
    1. Arizona
  8. Viral Therapy in Treating Patient With Liver Cancer
    1. Arizona
  9. Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
    1. Arizona
  10. A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors
    1. Arizona
    2. Minnesota
  1. 1
  2. 2
  3. 3
  4. Next
.

Mayo Clinic Footer